	Application No.	Applicant(s)
	09/132,521	NAGAI ET AL.
Notice of Allowability	Examiner	Art Unit
	Joseph T. Woitach	1632
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>July 6, 2004</u> .		
2. The allowed claim(s) is/are <u>1-8,11,12,14-18 and 20-23</u> .		
3. The drawings filed on April 15, 2003 are accepted by the Examiner.		
4.		
Attachment(s) 1. Notice of References Cited (PTO-892) 2. Notice of Draftperson's Patent Drawing Review (PTO-948) 3. Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ☐ Interview Summary Paper No./Mail Da 8), 7. ⊠ Examiner's Amend	ate

Application/Control Number: 09/132,521

Art Unit: 1632

DETAILED ACTION

This application is an original application filed August 11, 1998.

Applicants' amendment filed July 6, 2003, has been received and entered. Claims 9, 10, 13 and 19 have been canceled. Claims 1, 6, 11, 12, 14, 15, and 21 have been amended. Claims 1-8, 11, 12, 14-18 and 20-23 are pending and currently under examination.

REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance:

The claims have been amended to be consistent with claim changes Examiner indicated would be found allowable during the interview conducted March 19, 2004. The claims were rejected under 35 U.S.C. 103(a) as being unpatentable over Yu et al. and Bleul et al. in view of Hasan et al. (J. Gen. Vir. 78:2813-2820, 1997) and Czaplewski et al. Upon re-evaluation of the teachings of the references as a whole, Examiner agrees that there is insufficient motivation to specifically choose to combine the use of a Sendai virus for the expression of chemokines. While there was general motivation to use Sendai virus to express heterologous transgenes, in view of the numerous types of vectors known in the art there is no specific motivation to use them to express chemokines. Moreover, while it was demonstrated in the prior art that soluble forms of chemokines could be generated from using other types of vectors, the art does demonstrate that this is not the case in all context for all vectors suggesting that there is an empirical nature to the ability to successfully use any type of vector to express a chemokine. The

Application/Control Number: 09/132,521

Art Unit: 1632

claim amendments were proposed to more clearly and precisely set forth the claimed invention viewed as enabled and unobvious over the prior art of record.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph Woitach whose telephone number is (571) 272-0739.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Deborah Reynolds, can be reached at (571) 272-0734.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group analyst Dianiece Jacobs whose telephone number is (571) 272-0532.

Joseph T. Woitach

Joe World

Page 3